|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-6-30
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
To assess the efficacy, safety, and biologic activity of atacicept in tumor necrosis factor antagonist-naive patients with rheumatoid arthritis (RA) in whom the response to methotrexate treatment was inadequate.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1529-0131
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 by the American College of Rheumatology.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1782-92
|
|
pubmed:meshHeading |
pubmed-meshheading:21452294-Adult,
pubmed-meshheading:21452294-Aged,
pubmed-meshheading:21452294-Antirheumatic Agents,
pubmed-meshheading:21452294-Arthritis, Rheumatoid,
pubmed-meshheading:21452294-Double-Blind Method,
pubmed-meshheading:21452294-Female,
pubmed-meshheading:21452294-Flow Cytometry,
pubmed-meshheading:21452294-Humans,
pubmed-meshheading:21452294-Intention to Treat Analysis,
pubmed-meshheading:21452294-Male,
pubmed-meshheading:21452294-Methotrexate,
pubmed-meshheading:21452294-Middle Aged,
pubmed-meshheading:21452294-Odds Ratio,
pubmed-meshheading:21452294-Recombinant Fusion Proteins,
pubmed-meshheading:21452294-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial.
|
|
pubmed:affiliation |
Karolinska Institute, Stockholm, Sweden. ronald.van.vollenhoven@ki.se
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
